MAYNE PHARMA GROUP LIMITED — Director's Dealing 2019

Dec 8, 2019

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Mayne Pharma Group Limited
ABN	76 115 832 963

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Scott Anthony Richards
Date of last notice	10 Dec 2018

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct and indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Solium Nominees (Australia) Pty Ltd as nominee for Scott Richards (1) HSBC Nominees (Australia) Limited as nominee for Scott Anthony Richards (2) HSBC Nominees (Australia) Limited as nominee for Scott Anthony Richards & Susan Marie Richards (3)
Date of change	9 Dec 2019
No. of securities held prior to change	21,457,254 Ordinary Shares pursuant to Executive Share Loan Scheme (1) 3,862,906 Ordinary Shares (2) 1,722,463 OrdinaryShares(3)
Class	Ordinary Shares & Performance Rights
Number acquired	5,145,686 Ordinary Shares pursuant to the Executive Share Loan Scheme 2,555,805 Performance Rights pursuant to the Performance Right and Option Plan
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Loan shares acquired at $0.4695 (acquisition price being the weighted average price of Mayne Pharma fully paid ordinary shares in the 5 days from 22 November to 28 November 2019) Performance rights - Nil

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

No. of securities held after 26,602,940 Ordinary Shares pursuant to Executive Share Loan change Scheme (1) 3,862,906 Ordinary Shares (2) 1,722,463 Ordinary Shares (3) 2,555,805 Performance Rights pursuant to Performance Rights and Option Plan Nature of change Issue of loan shares and performance rights pursuant to Resolution Example: on-market trade, off-market trade, 4 in the Notice of Meeting for the Company’s 2019 Annual General exercise of options, issue of securities under Meeting. dividend reinvestment plan, participation in buy-back

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract Nature of interest Name of registered holder (if issued securities) Date of change

No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed

Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade toproceed during thisperiod?	N/a
If prior written clearance was provided, on what date was thisprovided?	N/a

• See chapter 19 for defined terms.

01/01/2011ME_131678062_1 (W2003)

Appendix 3Y Page 2